Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause
Vasomotor symptoms of menopause (VMS), otherwise known as hot flashes, can significantly impact women's quality of life. Up to 87% of women report hot flashes during or after their menopause transition, and can last for a median duration of 7.4 years. The current mainstay of treatment and the m...
Saved in:
Main Authors: | Melissa Conklin (Author), Nanette Santoro (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of Drospirenone-Containing Hormone Replacement Therapy to Reduce Vasomotor Symptoms of Menopause
by: Dana A. Brown, et al.
Published: (2013) -
Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
by: Uml, et al.
Published: (2012) -
Neurokinin-1 Receptor Antagonist Treatment in Polymicrobial Sepsis: Molecular Insights
by: Akhil Hegde, et al.
Published: (2010) -
Efficacy and safety of non-hormonal agents for vasomotor symptoms of menopause: A prospective, double-blind, placebo-controlled study
by: Viktor E. Radzinsky, et al.
Published: (2023) -
Comparative study of gabapentin and isoflavone in menopausal vasomotor symptoms
by: Savita Rani Singhal, et al.
Published: (2016)